Boston Scientific, Takeda Pharmaceuticals & more — 5 GI companies making waves this week

Here are updates on GI companies to note.

Advertisement

Corporate Knights included Japan’s Takeda Pharmaceuticals as one of its 2017 Global 100 Most Sustainable Corporations in the World Index. To earn the distinction, Corporate Knights measured Takeda’s performance on a 14-key performance indicator scale including categories like energy productivity, innovation capacity and safety performance.

Israel-based Check-Cap enrolled its first patient in a multi-center study as it works to earn a CE Mark for its C-Scan system. The C-Scan system uses ultra-low dose X-ray technology in an ingestible capsule to map the colon for polyps and abnormalities.

Marlborough, Mass.-based Boston Scientific; Austin, Texas-based Apollo Endosurgery; and Raynham, Mass.-based EndoEvolution are among key companies operating in the global automated suturing devices market. The increase of minimally invasive procedures is fueling market growth.

More articles on gastroenterology/endoscopy:
5 most read GI/endoscopy stories — Jan. 16 to Jan. 20, 2017
GI leader to know: Dr. Scott Arlin of Ohio Gastroenterology Group
AGA, partners a step closer to developing CME to improve IBD management

Boston Scientific, Takeda Pharmaceuticals & more — 5 GI companies making waves this week

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.